Related references
Note: Only part of the references are listed.The life-threatening eruptions of immune checkpoint inhibitor therapy
Emily L. Coleman et al.
CLINICS IN DERMATOLOGY (2020)
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review
Nolan J. Maloney et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis
Swapna S. Shanbhag et al.
OCULAR SURFACE (2020)
Development andValidation of a Risk Prediction Model for In-Hospital MortalityAmong Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10
Megan H. Noe et al.
JAMA DERMATOLOGY (2019)
Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions
Chuang-Wei Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects
Lauren A. Dalvin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Chie Sotozono et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis
B. Sassolas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Share Paper
